-+ 0.00%
-+ 0.00%
-+ 0.00%
Atossa Therapeutics CEO Steven Quay joins ARDD 2026 panel on clinical trials, regulatory pathways for aging diseases
Share
Listen to the news
Atossa Therapeutics CEO Steven Quay joins ARDD 2026 panel on clinical trials, regulatory pathways for aging diseases
  • Atossa Therapeutics CEO Steven Quay will speak at ARDD 2026 at Harvard University in Boston on Oct. 1, 2026.
  • Quay is slated for an 11:20 a.m.–12:00 p.m. ET panel on clinical trials and regulatory pathways for diseases of aging.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609240800PR_NEWS_USPR_____SF54668) on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending